2050-6511-14-31 2050-6511 Research article <p>Computational analysis of protein-protein interfaces involving an alpha helix: insights for terphenyl–like molecules binding</p> IsvoranAdrianaadriana.isvoran@cbg.uvt.ro CraciunDanacraciundana@gmail.com MartinyVirginievirginie.martiny@univ-paris-diderot.fr SperandioOlivierolivier.sperandio@inserm.fr MitevaAMariamaria.miteva@univ-paris-diderot.fr

Department of Biology and Chemistry, West University of Timisoara, 16 Pestalozzi, Timisoara 300115, Romania

Advanced Environmental Researches Laboratory, 4 Oituz, Timisoara 300086, Romania

Teacher Training Department, West University of Timisoara, 4 Blvd. V. Parvan, Timisoara 300223, Romania

Université Paris Diderot, Sorbonne Paris Cité, Molécules Thérapeutiques in silico, Inserm UMR-S 973, 35 rue Helene Brion, Paris 75013, France

INSERM, U973, Paris F-75205, France

BMC Pharmacology and Toxicology
<p>Computational, in silico and modeling studies </p>
2050-6511 2013 14 1 31 http://www.biomedcentral.com/2050-6511/14/31 10.1186/2050-6511-14-3123768251
231201311620131462013 2013Isvoran et al.; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Protein-Protein Interactions (PPIs) are key for many cellular processes. The characterization of PPI interfaces and the prediction of putative ligand binding sites and hot spot residues are essential to design efficient small-molecule modulators of PPI. Terphenyl and its derivatives are small organic molecules known to mimic one face of protein-binding alpha-helical peptides. In this work we focus on several PPIs mediated by alpha-helical peptides.

Method

We performed computational sequence- and structure-based analyses in order to evaluate several key physicochemical and surface properties of proteins known to interact with alpha-helical peptides and/or terphenyl and its derivatives.

Results

Sequence-based analysis revealed low sequence identity between some of the analyzed proteins binding alpha-helical peptides. Structure-based analysis was performed to calculate the volume, the fractal dimension roughness and the hydrophobicity of the binding regions. Besides the overall hydrophobic character of the binding pockets, some specificities were detected. We showed that the hydrophobicity is not uniformly distributed in different alpha-helix binding pockets that can help to identify key hydrophobic hot spots.

Conclusions

The presence of hydrophobic cavities at the protein surface with a more complex shape than the entire protein surface seems to be an important property related to the ability of proteins to bind alpha-helical peptides and low molecular weight mimetics. Characterization of similarities and specificities of PPI binding sites can be helpful for further development of small molecules targeting alpha-helix binding proteins.

Background

Protein-Protein Interactions (PPIs) are key to many cellular processes. Abnormal PPIs contribute to many disease states and as such, PPIs represent today a new class of drug targets essentially unexploited for drug discovery. Indeed, the size of the human interactome has been estimated to be between 300,000 1 and 650,000 interactions 2 . In the last decade many studies have been performed in order to target PPIs 3 . Several small-molecule inhibitors of PPIs have been demonstrated therapeutic potential 4 5 6 7 8 . However, efficient targeting of PPIs is still being considered as an important challenge 3 9 10 . In contrast to enzyme-substrate interactions, protein-protein recognition often occurs through flat surfaces or wide shallow grooves. Recent structural analyses of PPI interfaces and small molecules disrupting PPIs suggested that such ligands might mimic the structural characteristics of the protein partner 6 11 . To facilitate the discovery of new PPI small-molecule inhibitors, the characterization of PPI interfaces 12 13 and the prediction of putative ligand binding sites are essential. Physicochemical properties of both ligand and protein are key to mediate the binding 14 , such as cavity sizes, shape complementarity, electrostatic potential and hydrophobicity 12 15 .

The role of alpha-helical peptides in mediating many PPIs is well demonstrated and development of small organic molecules mimicking such peptides becomes important 16 . Recent studies have been carried out on the whole Protein Data Bank (PDB) in order to establish a druggability profile of alpha-helix mediated PPIs and to predict which of them could bind a small molecule 17 . More specifically, terphenyl and its derivates are small organic molecules 18 19 20 21 22 23 24 25 26 mimicking one face of an alpha-helical peptide, i.e. the side chains of three key residues occupying positions i, i+3 and i+7 25 26 or i, i+4 and i+7 20 of the bound helix. It has been suggested that terphenyl compounds can serve as pharmacological probes because they are membrane permeable 22 . Terphenyl 1 and 2, which mimic the calmodulin binding face of smooth muscle myosin light chain kinase (smMLCK), have been shown to inhibit the interactions of calmodulin (CaM) with the enzyme 3'-5'-cyclic nucleotide phosphodiesterase (PDE) and with the helical peptide C20W of the plasma membrane calcium pumps 18 . Following the similarity between the calmodulin and human centrin 2 (HsCen2) alpha-helix binding sites, we recently suggested that terphenyl 2 might also inhibit the interaction between HsCen2 and a 17 residues peptide of Xeroderma Pigmentosum Group C (XPC) protein 27 . Terphenyl derivates mimicking the alpha-helical structure of p53 N-terminal peptide inhibit the p53-MDM2 22 and the p53-HDM2 interactions 21 . These molecules also mimic the alpha-helical region of Bak BH3 domain, which binds BCL-X2, thus disrupting the BCL-X2/Bak interaction 19 20 24 .

In this work we performed a computational analysis in order to evaluate several key physicochemical and surface properties of proteins known to interact with alpha-helical peptides or to bind terphenyl and its derivatives. We calculated the binding pocket volumes and the fractal dimensions of the surface cavities for the entire protein and for the binding pockets. We identified several similarities and specificities characterizing such protein binding sites that can be helpful for future development of more efficient small-molecule inhibitors targeting alpha-helix binding proteins.

Methods

In this study we compared the sequence and surface properties of the investigated proteins. In order to analyze the sequence similarities we performed sequence alignment using the CLUSTALW software 28 . Interacting residues at the protein-protein interface in terms of contact distances were found using the ContPro online freely available tool 29 . We identified the protein residues interacting with the three key residues of the alpha-helical peptide (occupying positions i, i+3 and i+7 or i, i+4 and i+7) those relative positions are mimicked by terphenyl and its derivatives. The distance threshold was set to 5 Å for the side chain atoms.

In order to evaluate the protein surface properties, the bound peptide was removed for each complex. The surface characteristics of the entire protein and those of the peptide-binding cavity were analyzed. Using the approach of the fractal geometry we quantitatively described the surface roughness for the entire protein and for the binding cavity, expressed by global surface fractal dimension (DS) and local surface fractal dimension (DL), respectively. In order to calculate the surface fractal dimension we used the method proposed by Lewis and Rees 30 based on the scaling law between the surface area (SA) and the radius of the rolling probe molecule (R) on the surface, i.e. SA is proportional to the radius to the power 2-Ds:

SA ~ R 2 - D S

The surface fractal dimension was determined from the slope of the double logarithmical plot of SA versus R. The surface area of the protein was computed using the on-line available software GETAREA 31 . Probe radii of 1, 1.2, 1.4, 1.6, 1.8 and 2 Å were used. For the proteins cavities, the same algorithm was employed using the CASTp software 32 . Hydrophobicity and local hydrophobic density for binding pockets were determined using Fpocket 33 . Pocket volumes were computed using CASTp 32 .

Molecular docking of terphenyl 2 was performed into the alpha-helical binding sites of calmodulin (code entry 2O5G) and troponin C (code entry 1A2X) using AutoDock 4.2 34 . The input files preparation and docking analysis were carried out using AutoDockTools. Grid maps were centered in the alpha-helix binding site for both structures. Grids sizes were 126 Å x 126 Å x 126 Å with a grid spacing of 0.33 Å for calmodulin and 126 Å x 126 Å x 126 Å with a grid spacing of 0.28 Å for troponin C. Ligand conformational searching was performed using Lamarckian genetic algorithm and all ligand torsion angles were flexible. The following docking parameters were used: 250 Lamarckian genetic algorithm runs, a population size of 250, a maximum of 2 500 000 energy evaluations and a maximum of 27000 generations.

Figures were prepared using PyMol 35 and CHIMERA software 36 .

Results and discussions

Sequence-based analysis

We analyze several proteins interacting with alpha-helical peptides, some of them being known to bind also terphenyl and/or its derivatives. To characterize and compare their surface properties we examine the sequences and the three dimensional (3D) structures of the complexes formed by the protein and the bound peptide. The 3D structures are retrieved from the PDB 37 , the entry codes being presented in Table 1. Most of the structures are crystallographic. Two NMR structures are also used: the C-terminal domain of human centrin 2 in complex with the repeat sequence of human Sfi 1 and the human BCL-XL in complex with the BAK peptide.

<p>Table 1</p>

Protein complex

PDB code Resolution

SwissProt code

Interacting residues of the bound alpha-helix

*known to be disrupted by terphenyl or its derivatives.

Chicken calmodulin in complex with smooth muscle myosin light chain kinase (smMLCK)

2O5G*

P62149

TRP5, THR8, VAL12

1.08 Å

Human calmodulin in complex with a mutant peptide of human DRP-1 kinase

1ZUZ

P62158

TRP305, PHE309, VAL312

1.91 Å

Human calmodulin in complex with CAV1.1 IQ peptide

2VAY*

P62158

THR526, ILE529, PHE533

1.94 Å

Human calmodulin in complex with CAV2.2 IQ peptide

3DVE

P62158

MET854, VAL857, MET161

2.35 Å

E Coli calmodulin in complex with RS20 peptide of smMLCK

1QTX

-

TRP5, THR8, VAL12

1.65 Å

Rat calmodulin in complex with NMDA receptor NR1C1peptide

2HQW

P62161

PHE880, THR884, LEU887

1.90 Å

Human centrin 2 in complex with the centrin binding region of XPC protein

2GGM

P41208

TRP848, LEU851, LEU855

2.35 Å

C-terminal domain of human centrin 2 in complex with a repeat sequence of human Sfi 1

2K2I

P41208

LEU651, LEU655, TRP658

NMR

Scherffelia dubia centrin in complex with smMLCK peptide

3KF9

Q06827

TRP4, PHE8, VAL11

2.60 Å

Human BCL-XL in complex with BAK peptide

1BXL*

Q07817

VAL574, LEU578, ILE581

NMR

Human E3 ubiquitin-protein ligase MDM2 in complex with p53 tumor transactivation domain (fragment 17-125)

1YCR*

Q00987

PHE19, TRP23, LEU26

2.60 Å

Rabbit cardiac troponin C in complex with a fragment (residues 1-47) of cardiac troponin I

1A2X

P02586

LEU17, MET21, ILE24

2.30 Å

Protein – alpha-helical peptide complexes

Multiple sequences alignment (Figure 1) shows low sequence identity for the most of the analyzed proteins (shown in Table 2) both for the entire sequences and for the binding areas. The binding areas included all residues of the protein interacting with the alpha-helical peptide. Chicken, human, E. coli and rat calmodulin have very similar sequences (rat, chicken and human calmodulin are 100% identical; E coli has 98% identity with the others). For BCL-XL and human ubiquitin carboxyl-terminal hydrolase MDM2 only those fragments of sequences that are present in the 3D structures are considered. There is a high similarity only between the calmodulin, centrin 2 and troponin C sequences.

<p>Figure 1</p>

Sequence alignment of alpha-helix binding proteins

Sequence alignment of alpha-helix binding proteins. The amino acid residues interacting with alpha-helical peptides are presented in red.

<p>Table 2</p>

Protein/ sequence identity

Human calmodulin

Human centrin 2

Scherffelia dubia centrin

Human BCL-X 2

Human E3 ubiquitin-protein ligase MDM2

The binding area was defined here as all residues of the protein interacting with the helical peptide.

Human centrin 2

54/50

Scherffelia dubia centrin

56/55

90/74

Human BCL-X2

5/7

5/5

5/8

Human E3 ubiquitin-protein ligase MDM2

5/4

5/10

7/6

9/5

Rabbit cardiac troponin C

57/51

57/34

37/32

5/9

5/19

Sequence identity (in %) between the considered proteins (the binding area/entire protein)

Structure-based analysis

Figure 2 illustrates the complexes’ structures of six alpha-helix binding proteins. In all shown complexes, bulky hydrophobic residues of the bound peptide anchor into the protein binding pocket. Following the sequence similarities we superimposed the alpha-helix binding regions structures of calmodulin, human centrin 2, scherffelia dubia centrin and rabbit troponin C (Figure 3a). Strong structural homology for binding regions is seen following the sequence similarity of these proteins. Figure 3b and 3c illustrate the binding pockets of BCL-XL and human E3 ubiquitin-protein ligase MDM2, respectively.

<p>Figure 2</p>

3D structures of the complexes formed by

3D structures of the complexes formed by: (a) human centrin 2 and a 10 residue peptide of Xeroderma Pigmentosum group C protein, code entry 2GGM. (b) chicken calmodulin and smooth muscle myosin light chain kinase (smMLCK), code entry 2O5G. (c) scherffelia dubia centrin and smMLCK peptide, code entry 3KF9. (d) rabbit cardiac troponin C and a fragment of cardiac troponin I, code entry 1A2X. (e) human BCL-XL and BAK peptide, code entry 1BXL. (f) human E3 ubiquitin-protein ligase MDM2 and p53 tumor transactivation domain, code entry 1YCR. All proteins are shown as surface in atom color type (C and H-white, N – blue, O -red, S – yellow) and ligands are shown in magenta cartoon with hydrophobic interacting residues given as sticks.

<p>Figure 3</p>

3D structures of alpha-helix binding domains

3D structures of alpha-helix binding domains. (a) Superposition of the alpha-helix binding regions of chicken calmodulin (red, code entry 2O5G), HsCen2 (blue, code entry 2GGM), scherffelia dubbia centrin (green, code entry 3KF9) and rabbit troponin C (yellow, code entry 1A2X). (b) Structure of human BCL-XL binding domain (code entry 1BXL). (c) Structure of human E3 ubiquitin-protein ligase MDM2 (code entry 1YCR) binding domain.

The interacting residues of the proteins and bound peptides, identified with ContPro 29 , are shown in Figures 1 and 4 and Table 1. The results reveal that usually hydrophobic residues such as TRP, LEU, ILE, PHE, VAL, MET are involved in the interactions. The presence of hydrophobic residues suggests a favorable interaction with terphenyl-like molecules anchoring in the hydrophobic cavities. Most of the residues involved in the interactions between the proteins and alpha-helices are hydrophobic for both partners, as also observed in other studies 38 . We notice several key residues involved in the interaction of the same protein with different peptide partners. For example, in the case of calmodulin, PHE92, MET124, PHE141, MET144 and MET145 are involved in most of the peptides’ interactions. These residues can thus be considered as key for the interaction with terphenyl and its derivatives, or other alpha-helix mimetics. We noticed the presence of MET residues in most of the alpha-helix binding pockets analyzed here. In a recent study, MET residues have not been identified to be a part of hot spot amino acids, in particular in alpha-helix mediated protein interfaces 39 . However, our analysis clearly indicates their presence in positions that are key for the interaction with the alpha-helical partner. Furthermore, Ma and Nussinov 40 have also concluded that the amino acids TRP, MET, and PHE are important for protein-protein interactions. They showed that TRP/MET/PHE residues play roles in the dimerization of the transcriptase (p51/p66) and in cell-fusion processes, including the gp120-CD4 interaction and the gp41 six-helix bundle formation. They suggested that polarizability of MET allows it to assume roles of both hydrophobic and hydrophilic residues 40 . Further, its larger flexibility compared to other hydrophobic residues may facilitate the plasticity of hydrophobic binding pockets allowing to accommodate different ligands 27 .

<p>Figure 4</p>

Illustration of the interacting residues (in sticks) of the protein (atom color type) and the bound peptide (red)

Illustration of the interacting residues (in sticks) of the protein (atom color type) and the bound peptide (red): (a) chicken calmodulin and smMLCK (code entry 2O5G), (b) human centrin 2 and the centrin binding region of XPC (code entry 2GGM), (c) human BCL-XL protein and BAK (code entry 1BXL), (d) human E3 ubiquitin- protein ligase MDM2 and p53 tumor transactivation domain (code entry 1YCR), (e) rabbit cardiac troponin C and cardiac troponin I (code entry 1A2X).

We used Fpocket 33 and CASTp 32 to calculate geometrical and physicochemical characteristics of the binding pockets taking into account the protein residues interacting with the alpha-helical peptides. The overall hydrophobic character of the binding pockets is again clearly identified. Yet, some specificity is also observed, several pockets show high hydrophobicity score but low local hydrophobic density, or vice versa, demonstrating that the hydrophobic patches are not always regularly distributed in the binding pockets. For example, 1YCR and 3KF9 have similar hydrophobicity scores but high and low calculated hydrophobic density, respectively. The differences of the hydrophobicity distribution are illustrated in Figure 5.

<p>Figure 5</p>

Surface lipophilicity (shown in green) of alpha-helix-binding proteins computed using MOE

Surface lipophilicity (shown in green) of alpha-helix binding proteins computed using MOE. (a) Human E3 ubiquitin-protein ligase MDM2 (PDB code 1YCR), (b) Scherffelia dubia centrin (PDB code 3KF9).

The volumes of the detected pockets in the peptide-binding regions computed with CASTp are given in Table 3. The average volume of the sub-cavities present at the PPI interfaces found by Fuller et al 41 was ~60 Å 3 . Sonavane & Chakrabarti 42 found PPI pocket volumes to be up to ~330 Å 3 . We found similar volumes to those reported in Bourgeas et al. 43 . Taking into account the various algorithms and different concepts for binding pocket definition, such differences for the computed volumes can be expected. Several small cavities are present in the binding region (seen in Figure 2 and Figure 5), as it has been previously observed for other targeted PPI interfaces 39 . For the proteins studied here, the presence of several small hydrophobic cavities in the alpha-helix binding region seems to be a typical surface feature guiding the anchoring of hydrophobic residues from the peptide side. Such characteristics can also facilitate targeting PPI mediated by alpha-helices by small molecules containing hydrophobic anchors (as terphenyl or other mimetics).

<p>Table 3</p>

Protein code PDB

Volume (Å 3 )

Hydrophobicity score

Local hydrophobic density

Chicken calmodulin

312.0

68.86

43.00

2O5G

Human calmodulin

203.0

68.86

42.00

1ZUZ

Human calmodulin

219.8

59.62

40.00

2VAY

Human calmodulin

226.4

61.00

39.32

3DVE

E.coli calmodulin

317.9

56.63

40.15

1QTX

Rat calmodulin

310.6

56.62

43.78

2HQW

Human centrin 2

147.9

41.47

32.00

2GGM

Human centrin 2

210.9

39.93

35.08

2K2I

Scherffelia dubia centrin

221.5

58.19

31.00

3KF9

Human BCL-XL

321.5

36.91

42.04

1BXL

Human E3 ubiquitin-protein ligase MDM2

201.9

51.18

55.20

1YCR

Rabbit cardiac troponin C

213.1

63.07

39.15

1A2X

Geometrical and physicochemical characteristics of the identified pockets

Further, we decided to explore the roughness of the alpha-helix binding sites. The methodology implemented to calculate the fractal surface dimensions, used for the roughness evaluation, is illustrated in Figure 6 for the global surface roughness of chicken calmodulin. The fractal global surface dimension and the fractal local surface dimension for the binding site of chicken calmodulin are calculated to be DS=2.238; ± 0.006 and DL= 2.616 ± 0.072, respectively. The global and local fractal dimensions for the other proteins are given in Table 4. Our results and other previously published data 44 45 46 47 suggest that the global fractal dimension of protein surface is about 2. The local surface fractal dimensions for the binding cavities are computed to be larger than the global surface fractal dimensions for all studied proteins. This reflects the higher roughness of the binding site and its more complex shape and that can be considered as important for ligand binding. The most important differences between DS and DL are obtained for human calmodulin (2VAY), centrin (3KF9, 2K2I), BCL-XL (1BXL), MDM2 (1YCR) and troponin C (1A2X). It has been experimentally demonstrated that human calmodulin 18 , BCL-XL 19 20 and MDM2 21 22 interact with terphenyl or its derivatives. Recently, we suggested a possible binding of terphenyl 2, which mimics the relative positions of the side chains of residues TRP848, LEU851, LEU855 of the XPC peptide, into human centrin 2 following our energetic and conformational flexibility analysis performed for the alpha-helical peptide-binding pocket of centrin 2 27 . The DL value for the peptide-binding site of troponin C shows rougher surface than the entire protein, similarly to the above listed terphenyl-binding proteins.

<p>Figure 6</p>

Double logarithmical plot of the surface area versus probe radii for chicken calmodulin (PDB code 2O5G)

Double logarithmical plot of the surface area versus probe radii for chicken calmodulin (PDB code 2O5G).

<p>Table 4</p>

Code PDB

D S

D L

2O5G

2.238 ± 0.006

2.616 ± 0.072

1ZUZ

2.181 ± 0.007

2.487 ± 0.058

2VAY

2.183 ± 0.006

2.757 ± 0.108

3DVE

2.217 ± 0.003

2.418 ± 0.040

1QTX

2.302 ± 0.002

2.494 ± 0.069

2HQW

2.172 ± 0.002

2.454 ± 0.082

2GGM

2.247 ± 0.004

2.373 ± 0.018

2K2I

2.167 ± 0.008

2.892 ± 0.124

3KF9

2.179 ± 0.006

2.892 ± 0.153

1BXL

2.230 ± 0.007

2.696 ± 0.225

1YCR

2.173 ± 0.014

2.708 ± 0.055

1A2X

2.177 ± 0.005

2.624 ± 0.032

Global (D S ) and local (D L ) surface fractal dimensions of investigated proteins

Taking into consideration the sequence and structural homology of troponin C and calmodulin and other physicochemical similarities of the binding sites as discussed above, we decided to probe putative terphenyl binding into troponin C. We performed docking of terphenyl 2 into the peptide-binding sites of calmodulin and troponin C using AutoDock. The best scored docking poses are shown in Figure 7. The terphenyl orientations in the best scored poses correspond to the position of the bound alpha-helical peptides shown in Figure 2. The predicted interaction energies of -7.98 and -8.18 kcal/mol for terphenyl binding in calmodulin and troponin C, respectively, suggest favorable interactions with the two proteins.

<p>Figure 7</p>

Best scored docking poses of terphenyl. The poses after docking-scoring with AutoDock are shown in cyan

Best scored docking poses of terphenyl. The poses after docking-scoring with AutoDock are shown in cyan. (a) chicken calmodulin, code entry 2O5G, (b) rabbit cardiac troponin C, code entry 1A2X.

In the light of the results obtained here, it is now interesting to discuss the physicochemical properties of known PPI modulators, such as terphenyl. In a previous work 10 we gathered a set of 66 PPI inhibitors among which some terphenyl derivatives and other inhibitors of alpha-helix mediated PPI were present. In that work we demonstrated the more hydrophobic character of these compounds but also their bigger size. Interestingly, we also showed the importance of a critical number of aromatic bonds and some specific molecular shapes (T-shaped, star-shaped, or L-shaped compounds), among which some correspond to terphenyl derivatives. The present work therefore confirms that such genuine properties on the ligand side seem to be cavity-driven, and that these small molecules must possess certain properties in order to efficiently modulate an alpha-helix mediated PPI and to mimic the native partner and its properties.

Conclusions

Modulating protein-protein interactions using small molecules based on surface recognition has been a field of increasing interest during the last decade. PPI interfaces are very complex and need to be analyzed in order to be efficiently targeted for drug discovery purposes. Designed compounds must bind with high affinity and selectivity to the target protein. The low sequence identity found between some of the analyzed proteins suggests that there are no sequence requirements for the ability of proteins to bind alpha-helical peptides and consequently small-molecule mimetics.

From the structural point of view, all investigated proteins show larger surface fractal dimensions for the peptide-binding pockets than the entire protein surface reflecting the higher complexity of the shape of the binding sites. Also, the presence of several hydrophobic patches at the protein surface seems to be an important property related to the ability of the protein to bind alpha-helical peptides and mimetics. Furthermore, we showed that hydrophobicity is not uniformly distributed across different alpha-helix binding pockets and that its distribution can be used to identify hydrophobic hot spots.

Many similarities between the binding sites studied here are observed and terphenyl or its derivatives binding to various alpha-helix binding proteins can be suggested. However, targeting various PPI complexes by similar small molecules can rise selectivity problems in the context of drug discovery or chemical biology projects. Thus, the specificities found here for different binding sites, e.g. key residues, roughness and local hydrophobic density, can be further exploited to optimize terphenyl-like ligands in order to improve their selectivity.

Abbreviations

PPI: Protein-Protein interactions; smMLCK: smooth muscle myosin light chain kinase; CaM: Calmodulin; HsCen2: Human centrin 2; PDE: 3'-5'-cyclic nucleotide phosphodiesterase; XPC: Xeroderma pigmentosum group C.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AI carried out the sequence alignment and binding pockets analysis. DC carried out the fractal calculations. AI and DC drafted the manuscript. VM carried out the volume calculations and docking analysis. OS participated in the protein-protein interface analysis and discussion writing. MAM designed and coordinated the study. All authors participated in manuscript writing and approved the final manuscript.

Acknowledgments

The financial support from the West University of Timisoara, the Inserm institute and the University Paris Diderot is greatly appreciated.

<p>Structure-based prediction of protein-protein interactions on a genome-wide scale</p>HunterTManiatisTCalifanoAHonigBZhangQCPetreyDDengLQiangLShiYThuCABisikirskaBLefebvreCAcciliDNature201249055666010.1038/nature11503348228823023127<p>Estimating the size of the human interactome</p>StumpfMPThorneTde SilvaEStewartRAnHJLappeMWiufCProc Natl Acad Sci USA20081056959696410.1073/pnas.0708078105238395718474861<p>Exploring biology with small organic molecules</p>StockwellBRNature200443284685410.1038/nature03196316517215602550<p>Small-molecule inhibitors of IL-2/IL-2R: Lessons learned and applied</p>WilsonCGArkinMRCurr Top Microbiol Immunol2011348252920703966<p>In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics</p>VilloutreixBOBastardKSperandioOFahraeusRPoyetJLCalvoFDeprezBMitevaMACurr Pharm Biotechnol2008910312210.2174/13892010878395521818393867<p>Protein-protein interactions as targets for small molecule drug discovery</p>FryDCBiopolymers20068453555210.1002/bip.2060817009316<p>Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening</p>GautierBMitevaMAGoncalvesVHuguenotFCoricPBouazizSSeijoBGaucherJFBroutinIGarbayCLesnardARaultSInguimbertNVilloutreixBOVidalMChem Biol201118121631163910.1016/j.chembiol.2011.10.01622195565<p>Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening</p>VilloutreixBOLacondeGLagorceDMartineauPMitevaMADariavachPPLoS One201166e2111710.1371/journal.pone.0021117311880121701581<p>Reaching for high-hanging fruit in drug discovery at protein-protein interfaces</p>WellsJAMcClendonCLNature20074501001100910.1038/nature0652618075579<p>Rationalizing the chemical space of protein-protein interaction inhibitors</p>SperandioOReynesCHCamprouxACVilloutreixBODrug Discov Today20101522022910.1016/j.drudis.2009.11.00719969101<p>Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I)</p>MorelliXBourgeasRRochePCurr Opin Chem Biol20111547548110.1016/j.cbpa.2011.05.02421684802<p>A Novel and Efficient Tool for Locating and Characterizing Protein Cavities and Binding Sites</p>TripathiAKelloggGEProteins201078482584210.1002/prot.22608281176719847777<p>Protein-protein Docking and Hot-spot Prediction for Drug Discovery</p>GrosdidierSFernández-RecioJCurr Pharm Des201218304607461810.2174/13816121280265159922650255<p>Mapping of ligand-binding cavities in proteins</p>AnderssonCDChenBYLinussonAProteins201078614081422295748420034113<p>Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists</p>KoesDKhouryKHuangYWangWBistaMPopowiczGMWolfSHolakTADomlingACamachoCJPLoS One201273e3283910.1371/journal.pone.0032839329969722427896PetskoGARingeDProtein structure and functionLondon: New Science Press Ltd2004<p>Assessing helical protein interfaces for inhibitor Design</p>BullockBNJochimALAroraPSJ Am Chem Soc201113336142201422310.1021/ja206074j316872321846146<p>Towards Proteomimetics: Terphenyl Derivatives as Structural and Functional Mimics of Extended Regions of an a-Helix</p>OrnerBPErnstJTHamiltonADJ Am Chem Soc2001123225382538310.1021/ja002554811457415<p>Development of a Potent Bcl-xL Antagonist Based on r-Helix Mimicry</p>KutzkiOParkHSErnstJTOrnerBPYinHHamiltonADJ Am Chem Soc200212440118381183910.1021/ja026861k12358513<p>Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL</p>YinHLeeGISedeyKAKutzkiOParkHSOrnerBPErnstJTWangHGSebtiSMHamiltonADJ Am Chem Soc200512729101911019610.1021/ja050122x16028929<p>Terphenyl-Based Helical Mimetics That Disrupt the p53/HDM2 Interaction</p>YinHLeeGParkHSPayneGARodriguezJMSebtiSMHamiltonADAngew Chem2005117182764276710.1002/ange.200462316<p>p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53</p>ChenLYinHFarooqiBSebtiSHamiltonADChenJMol Canc Ther2005461019102510.1158/1535-7163.MCT-04-0342<p>Protein recognition motifs: design of peptidomimetics of helix surfaces</p>CheYBrooksBRMarshallGRBiopolymers200786428829710.1002/bip.2074417443711<p>Inhibition of protein-protein interaction by peptide mimics</p>BecerrilJRodriguezJMWyrembakPNHamiltonADProtein Surface Recognition: Approaches for Drug DiscoveryLondon: John Willey&SonsGiralt E, Peczuh M, Salvatella X2011<p>Towards protein surface mimetics</p>FairlieDPWestMLWongAKCurr Med Chem19985129629481033<p>Synthesis and structure of 1,4-dipiperazino benzenes: chiral terphenyl-type peptide helix mimetics</p>MaityPKönigBOrg Lett20081071473147610.1021/ol800274918335950<p>Exploring NMR ensembles of calcium binding proteins: Perspectives to design inhibitors of protein-protein interactions</p>IsvoranABadelACraescuCTMironSMitevaMABMC Struct Biol2011112410.1186/1472-6807-11-24311646321569443<p>CLUSTAL W: lmproving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice</p>ThompsonJDHigginsDGGibsonTJNucleic Acids Res1994224673468010.1093/nar/22.22.46733085177984417<p>ContPro: A web tool for calculating amino acid contact distances in protein from 3D –structure at different distance threshold</p>FirozAMalikAAfzalOJhaVBioinformation201052555710.6026/97320630005055303998921346863<p>Fractal surfaces of proteins</p>LewisMReesDCScience19852301163116510.1126/science.40710404071040<p>Exact and efficient analytical calculation of accesible surface areas and their gradients for macromolecules</p>FraczkiewiczRBraunWJ Compl Chem19981931933310.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W<p>CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated resiudes</p>DundasJOuyangZTsengJBinkowskiATurpazYLiangJNucleic Acid Res200634W116W11810.1093/nar/gkl282153877916844972<p>Fpocket; An open source platform for ligand binding pocket detection</p>GuilleouxVLSchmidtkePTufferyPBMC Bioinforma20091016810.1186/1471-2105-10-168<p>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</p>MorrisGMHueyRLindstromWSannerMFBelewRKGoodsellDSOlsonAJJ Comput Chem200930162785279110.1002/jcc.21256276063819399780DeLanoWLThe PyMol molecular graphics systemSan Carlos: DeLano Scientific2002<p>UCSF Chimera--a visualization system for exploratory research and analysis</p>PettersenEFGoddardTDHuangCCCouchGSGreenblattDMMengECFerrinTEJ Comput Chem200425131605161210.1002/jcc.2008415264254<p>The Protein Data Bank</p>BermanHMWestbrookJFengZGillilandGBhatTNWeissigHShindyalovINBournePENucleic Acids Res20002823524210.1093/nar/28.1.23510247210592235<p>Hot spots—A review of the protein–protein interface determinant amino-acid residues</p>MoreiraISFernandesPARamosMJProteins Struct Funct Bioinform200768480381210.1002/prot.21396<p>Assessing Helical Protein Interfaces for Inhibitor Design</p>BrookeNBullockAParamjitSAJ Am Chem Soc201113336142201422310.1021/ja206074j316872321846146<p>Trp/Met/Phe Hot Spots in Protein-Protein Interactions: Potential Targets in Drug Design</p>MaBNussinovRCurr Top Med Chem20077999100510.2174/15680260778090671717508933<p>Predicting druggable binding sites at the protein–protein interface</p>FullerJCBurgoyneNJJacksonRMDrug Discov Today2009143–415516119041415<p>Cavities and Atomic Packing in Protein Structures and Interfaces</p>SonavaneSChakrabartiPPLoS Comput Biol20084e100001188<p>Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database</p>BourgeasRBasseMJMorelliXRochePPLoS One20103e9598<p>Self similarity of protein surfaces</p>GoetzeTBrickmannJBiophys J19926110911810.1016/S0006-3495(92)81820-912602271540684<p>Protein surface roughness and small molecular binding sites</p>PettitFKBowieJUJ Mol Biol199928541377138210.1006/jmbi.1998.24119917382<p>Predicting protein function from structure: Unique structural features of proteases</p>StawiskiEWBaucomAELohrSCGregoretLMProc Natl Acad Sci2000973954395810.1073/pnas.0705489971812310759560<p>Progress in predicting protein structure from sequence: unique features of O-glycosidases</p>StawiskiEWMandel-GoutfreundYLowenthalACGregoretLMPacific Symp Biocomput20027637648

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/2050-6511/14/31/prepub